Skip to main content

Skip to menu

Selection Jury

Selection Jury members are appointed by Harold Hamm Diabetes Center representatives with priority given to individuals who have served in international capacities in the field of diabetes research such as editors of major diabetes journals or recent leaders of major diabetes-related organizations.

Members of the 2015 Selection Jury

Dr. Kenneth Copeland Kenneth Copeland, MD, Selection Jury Chairperson

Kenneth C. Copeland, M.D., holds the CMRI Paul and Ann Milburn Chair in Pediatric Diabetes, is chief of the Diabetes and Endocrinology Section within the Department of Pediatrics at the University of Oklahoma Health Sciences Center, and is Director of children’s programs of the Harold Hamm Diabetes Center. Dr. Copeland is an experienced clinician researcher with special interests in Type 1 and Type 2 diabetes in children, growth, obesity and puberty. He has published more than 150 papers, editorials and book chapters, including the American Diabetes Association standards of care for children with Type 1 diabetes, and the current American Academy of Pediatrics clinical practice guidelines on the management of newly diagnosed type 2 diabetes mellitus in children and adolescents. Dr. Copeland has been awarded more than $20,000,000 in NIH funding for his work on youth with type 2 diabetes. For the last decade, he has served as the national co-chair and Oklahoma principal investigator of the NIH-sponsored Treatment Options for Type 2 diabetes in Adolescents and Youth (TODAY) study. Dr. Copeland’s honors include the CMRI Research Achievement Award (2003), the American Diabetes Association Oklahoma Chapter’s Father-of-the-Year Award (2011), and the Edith Kinney Gaylord Presidential Professorship, OUHSC (2013). Copeland is Past-President of the national Pediatric Endocrine Society (2006-2007).



Prof. Ferrannini received his MD from the University of Pisa school of Medicine. He currently serves as Professor of Internal Medicine at the University of Pisa School of Medicine; Chief of the Metabolism Unit of the CNR (National Research Council) Institute of Clinical Physiology, Pisa; and Clinical Professor of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, Texas. He has published over 600 original papers in the field of diabetes, metabolism and hypertension. Prof. Ferrannini is a founding member of the Italian Society of Obesity for which he has been President, has served on the Executive Council of the European Association for the Study of Diabetes (EASD) for which he has been President, and has been the Editor-in-Chief of the official Journal of EASD (Diabetologia, 1994-1997). He is the Chairman of the European Group for the Study of Insulin Resistance and a member of the EASD Foundation. He was the recipient of the 43rd Claude Bernard Lecture.

KlingensmithDr. Klingensmith is Professor of Pediatrics at the University of Colorado School of Medicine and the Barbara Davis Center for Childhood Diabetes. She received her MD from Duke University School of Medicine before training in pediatric endocrinology at Johns Hopkins University. Dr. Klingensmith was the Director of the Pediatric Clinical Care and Translation Research Division of the Barbara Davis Center from 1994-2011. She has been the Director of the National Institutes of Health funded pediatric endocrine diabetes fellowship training grant for the past 14 years as well as a NIH funded Scientist to train young investigators in diabetes research. Dr. Klingensmith’s major research interests have been in the epidemiology of type 1 diabetes, both the usual epidemiology of prevalence and incidence of childhood diabetes through the SEARCH for diabetes study, but also the epidemiology of diabetes autoimmunity in high risk children and youth as an active investigator in NIH sponsored DAISY and TEDDY studies.

RizzaDr. Rizza attended medical school at the University of Florida in Gainesville and completed his internship and residency at Johns Hopkins University. Dr. Rizza completed both a clinical endocrinology and a research fellowship at the Mayo Clinic. Dr. Rizza joined the faculty at Mayo in 1980 where he was chair of the Division of Endocrinology, Diabetes, Metabolism and Nutrition from 1992 to 2002, Co-Director of the Mayo Clinic Robert and Arlene Kogod Program on Aging from 2002-2004, the principle investigator for Mayo’s Center for Translation Science Activities (CTSA) from 2006-2013 and the Ronald F. Kinney Executive Dean for Research from 2005 to 2013. Dr. Rizza has received the American Diabetes Association’s Outstanding Physician Clinician Award and Banting Medal for Scientific Achievement, as well as the American Association of Clinical Endocrinologist’s Distinguished Service to Endocrinology Award. Seaquist Dr. Seaquist received her MD, as well as completed her internship and residency, at the University of Minnesota where she serves as Professor of Medicine today. Her research interests looks at the effects of diabetes on brain metabolism, structure and function. She is currently heading projects to learn how the brain adapts to diabetes and recurrent hypoglycemia with the long term goal of developing new therapies for the disease. She also leads the NIH funded ACCORDION (Action to control cardiovascular risk in diabetes follow on study) and the Eli Lilly funded Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) study and is principal investigator on the NIH funded T32 training grant in diabetes, endocrinology, and metabolism. Currently, Seaquist is leading the University of Minnesota site for glycemia reduction approaches in diabetes (GRADE), which are NIH and clinically funded trials focused on identifying the best treatments for patients with type 2 diabetes.
Weir Dr. Weir received his MD from Harvard Medical School and has been at Joslin Diabetes Center since 1984. Dr. Weir is the Co-Head of the Section on Islet Biology and Regenerative Medicine, and holds the Diabetes Research and Wellness Foundation Chair at the Joslin Diabetes Center. He is also a Professor of Medicine at Harvard Medical School. Until recently he has served as Director of Diabetes Endocrinology Research Center of Joslin Diabetes Center, which is supported by the National Institutes of Health, and as Head of the Diabetes Program of the Harvard Stem Cell Institute. Dr. Weir has been active in clinical care of diabetes and his research is focused on pancreatic islets, which contain insulin-secreting beta cells. Another facet of his work is to better understand the dysfunctional insulin secretion that is found in type 2 diabetes. Dr. Weir is also leading a multi-center clinical trial to determine if alpha-1 antitrypsin can slow the destruction of beta cells is individuals with new-onset type 1 diabetes.  


Members of the 2013 Selection Jury

Timothy Lyons, MD, FRCP, Selection Jury CHairpersonTimothy Lyons, MD, FRCP, Selection Jury Chairperson

Dr. Lyons holds the position of Director of the Diabetes Research Program and Professor of Diabetes and Translational Medicine at the Queen's University of Belfast.  He is also Professor of Research at the University of Oklahoma and a Member of the Harold Hamm Diabetes Center at the University of Oklahoma.  He has served as the past Chair of the American Diabetes Association's Research Policy Committee and was a member of the American Diabetes Association's 71st Scientific Sessions Planning Committee. 



BuseJohn Buse, MD, PhD, CDE -- Dr. Buse received his MD and PhD from Duke University in Durham, North Carolina before training in internal medicine and endocrinology at the University of Chicago. He is currently a professor at the University of North Carolina (UNC) School of Medicine in Chapel Hill, North Carolina where he also serves as the Chief of the Division of Endocrinology, Director of the Diabetes Care Center and Executive Associate Dean for Clinical Research.

GaleEdwin Gale, MD -- Prof Gale is Emeritus Professor of Diabetic Medicine and former Head of the University Department of Clinical Science in North Bristol. His major research interests have been in the pathogenesis of type 1 diabetes, but he has written reviews and opinion pieces on many aspects of diabetes, and was Editor of Diabetologia from 2003-2010. He has chaired the Special Advisory Group on diabetes and endocrinology for the European Medicines Agency (EMA) for the past 5 years. He is currently engaged in setting up Diapedia, an online open-access living textbook of diabetes.

HowardBarbara Howard, PhD -- Dr. Howard is the Senior Scientist and former president of MedStar Health Research Institute. She received her PhD in Microbiology from the University of Pennsylvania and currently holds a faculty appointment in the Department of Medicine at Georgetown University. Dr. Howard serves on several Data Safety Monitoring Boards for federal studies and on the editorial boards of numerous scientific journals. She has chaired the Nutrition Committee and The Council on Nutrition Physical Activity and Metabolism of the American Heart Association. Dr. Howard also chaired the Nutrition Study Section of the National Institutes of Health and served as a member of the NTH Expert Panel on Obesity that developed guidelines for the treatment and prevention of obesity.

RobertsonPaul Robertson, MD -- Dr. Robertson received his MD from Creighton Medical School before training in endocrinology at the University of Washington, where he is currently a Professor of Medicine and Pharmacology. Dr. Robertson has served as the American Diabetes Association President for Medicine and Science; Editor-in-Chief of Translations in Endocrinology and Metabolism, Endocrine Reviews, and Diabetes.

StanleyCharles Stanley, MD -- Dr. Stanley is the medical director of the Congenital Hyperinsulinism Center at The Children's Hospital of Philadelphia and a professor emeritus of pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He has published numerous articles in journals such as The New England Journal of Medicine, Journal of Pediatrics, Diabetes, Journal of Clinical Endocrinology and Metabolism, and The Journal of Biological Chemisty. He was recently co-editor of Monogenic Hyperinsulinemic Hypoglycemia Disorders, volume 21 of "Frontiers in Diabetes."